Dheyauldeen, Sinan <br/><br/>
Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.  [electronic resource] 

 -  The Laryngoscope  Jun 2012 
 - 1210-4 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1531-4995 
<br/><br/><label>Standard No.: </label>10.1002/lary.23303  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intranasal<br/>Adult<br/>Aged<br/>Anesthesia, Local<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Bevacizumab<br/>Drug Administration Schedule<br/>Epistaxis--drug therapy<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Injections, Intralesional<br/>Male<br/>Middle Aged<br/>Nasal Cavity--anatomy & histology<br/>Nasal Mucosa--drug effects<br/>Pilot Projects<br/>Premedication--methods<br/>Preoperative Care--methods<br/>Prospective Studies<br/>Recurrence<br/>Risk Assessment<br/>Severity of Illness Index<br/>Telangiectasia, Hereditary Hemorrhagic--complications<br/>Time Factors<br/>Treatment Outcome